JP2001503775A - T細胞の活性化に関係する疾患を治療するために有用なグアニルヒドラゾン - Google Patents
T細胞の活性化に関係する疾患を治療するために有用なグアニルヒドラゾンInfo
- Publication number
- JP2001503775A JP2001503775A JP52280198A JP52280198A JP2001503775A JP 2001503775 A JP2001503775 A JP 2001503775A JP 52280198 A JP52280198 A JP 52280198A JP 52280198 A JP52280198 A JP 52280198A JP 2001503775 A JP2001503775 A JP 2001503775A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- hiv
- compounds
- disease
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.T-細胞の活性化を特徴とする障害又は疾患を治療する方法であって、次式 で表す化合物又はその塩の有効量を、患者に投与することを含んでいる前記方法 。 (式中X2は、GhyCH-、GhyCCH3-又はH-であり;X1、X1及びX'2は、個別に、GhyCH -又はGhyCCH3-であり;Zは、-NH(CO)NH-,-(C6H4)-,-(C5NH3)-又は-A-(CH2)n-A -(n=2-10で、これは非置換体、モノ又はジC-メチル置換体、あるいはモノ又は ジ不飽和誘導体)であり;そしてAは、個別に、-NH(CO)-,-(CO)NH-,-NH(CO)NH -,-NH-又は-O-である) 2.X2がGhyCH-又はGhyCCH3-である場合、X2が、X1に対してメタ又はパラの位 置にあり、そしてX'2が、X'1に対してメタ又はパラの位置にある、請求項1の方 法。 3.前記化合物が、N,N'−ビス(3,5-ジアセチルフェニル)デカンジアミドテ トラキス(アミジンノヒドラゾン)テトラヒドロクロライドである、請求項2の 方法。 4.前記障害が、HIV感染である、請求項1の方法。 5.前記疾患が、自己免疫疾患である、請求項1の方法。 6.前記疾患が、ウイルス感染に起因する、請求項1の方法。 7.前記疾患が、全身性エリテマトーデス、インスリン依存性糖尿病、リウマ チ様関節炎、甲状腺炎、乾せん、移植片対宿主疾患、移植片拒絶、及び多発性硬 化症の中から選択される自己免疫疾患である、請求項5の方法。 8.T細胞の活性化を特徴とする障害又は疾患を治療する方法であって、p38 M APKシグナル伝達経路の構成要素の遺伝子発現を阻害することができる薬剤の有 効量を、患者に投与することを含んでいる前記方法。 9.前記薬剤が、p38 MAPKに相補的なアンチセンス分子である、請求項8の方 法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3106196P | 1996-11-15 | 1996-11-15 | |
US60/031,061 | 1996-11-15 | ||
PCT/US1997/020670 WO1998020868A1 (en) | 1996-11-15 | 1997-11-14 | Guanylhydrazones useful for treating diseases associated with t cell activation |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001503775A true JP2001503775A (ja) | 2001-03-21 |
Family
ID=21857458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52280198A Ceased JP2001503775A (ja) | 1996-11-15 | 1997-11-14 | T細胞の活性化に関係する疾患を治療するために有用なグアニルヒドラゾン |
Country Status (9)
Country | Link |
---|---|
US (3) | US6143728A (ja) |
EP (1) | EP0963197B1 (ja) |
JP (1) | JP2001503775A (ja) |
AT (1) | ATE454141T1 (ja) |
AU (1) | AU746647B2 (ja) |
CA (1) | CA2271693C (ja) |
DE (1) | DE69739734D1 (ja) |
ES (1) | ES2339306T3 (ja) |
WO (1) | WO1998020868A1 (ja) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69739734D1 (de) * | 1996-11-15 | 2010-02-25 | Cytokine Pharmasciences Inc | Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten |
US6696440B1 (en) * | 1999-01-07 | 2004-02-24 | Warner-Lambert Company | Treatment of asthma with MEK inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
EP1255541B1 (en) * | 2000-02-02 | 2005-11-09 | Dorian Bevec | Aromatic guanylhydrazone for the treatment of resistant viral infections |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
AU2001269092A1 (en) * | 2000-06-27 | 2002-01-08 | Axxima Pharmaceuticals Ag | Inhibitors of hepatitis b virus infection |
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
JP4636486B2 (ja) | 2002-02-11 | 2011-02-23 | バイエル、ファーマシューテイカルズ、コーポレイション | 脈管形成阻害活性を有するアリール尿素 |
CA2476896A1 (en) * | 2002-02-26 | 2003-09-04 | North Shore-Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
EP1389480A1 (en) * | 2002-08-14 | 2004-02-18 | Mondobiotech Interferon SA | Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
PL1636585T3 (pl) | 2003-05-20 | 2008-10-31 | Bayer Healthcare Llc | Diarylowe pochodne mocznika inhibowane kinazą |
EP1631145A4 (en) * | 2003-06-06 | 2009-12-23 | Univ Pennsylvania | P38 KINASEHEMMER COMPOSITION AND METHOD FOR THEIR USE |
JP4777887B2 (ja) | 2003-07-23 | 2011-09-21 | バイエル、ファーマシューテイカルズ、コーポレイション | 病気および状態の処置および防止のためのフロロ置換オメガカルボキシアリールジフェニル尿素 |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
AU2005225458B2 (en) | 2004-03-25 | 2008-12-04 | The Feinstein Institutes For Medical Research | Neural tourniquet |
US7244765B2 (en) * | 2004-06-25 | 2007-07-17 | Cytokine Pharmasciences, Inc | Guanylhydrazone salts, compositions, processes of making and methods of using |
JP5198863B2 (ja) * | 2004-08-17 | 2013-05-15 | サイトカイン ファーマサイエンシズ インコーポレイティド | グアニルヒドラゾン化合物、組成物、製造方法および使用方法 |
US20060253100A1 (en) | 2004-10-22 | 2006-11-09 | Medtronic, Inc. | Systems and Methods to Treat Pain Locally |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
WO2006073484A2 (en) | 2004-12-27 | 2006-07-13 | North Shore-Long Island Jewish Research Institute | Treating inflammatory disorders by electrical vagus nerve stimulation |
DE102006028371A1 (de) * | 2006-06-19 | 2007-12-20 | Rheinische Friedrich-Wilhelms Universität | Mittel gegen Malaria |
WO2008002465A2 (en) * | 2006-06-23 | 2008-01-03 | The Feinstein Institute For Medical Research | INHIBITORS OF Aβ AND SYNUCLEIN AGGREGATION |
US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
USRE48948E1 (en) | 2008-04-18 | 2022-03-01 | Warsaw Orthopedic, Inc. | Clonidine compounds in a biodegradable polymer |
US8412338B2 (en) | 2008-11-18 | 2013-04-02 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflamatory stimulation |
US20100239632A1 (en) | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
AU2010258792B2 (en) | 2009-06-09 | 2015-07-02 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
EP3636314B1 (en) | 2009-12-23 | 2021-09-08 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
WO2012021964A1 (en) * | 2010-08-18 | 2012-02-23 | UNIVERSITé LAVAL | Compounds and therapeutic applications related to inhibition of dendritic cell immunoreceptor (dcir) activity and signaling events |
WO2012154865A2 (en) | 2011-05-09 | 2012-11-15 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
US10314501B2 (en) | 2016-01-20 | 2019-06-11 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL8901507A (nl) * | 1989-06-14 | 1991-01-02 | Tno | Vluchtige aardkalimetaal-organische verbindingen en werkwijze voor de bereiding van gelaagde materialen met aardkalimetaaloxiden of -fluoriden uit deze verbindingen. |
DD299041A5 (de) * | 1989-08-29 | 1992-03-26 | Berlin-Chemie Ag,De | Verfahren zur herstellung eines mittels gegen retrovirale erkrankungen |
DD292376A5 (de) * | 1989-08-29 | 1991-08-01 | Berlin-Chemie Ag,De | Verfahren zur herstellung eines mittels gegen retrovirale erkrankungen |
DD299038A5 (de) * | 1989-08-29 | 1992-03-26 | Berlin-Chemie Ag,De | Verfahren zur herstellung eines mittels gegen retrovirale erkrankungen |
US4969305A (en) * | 1989-08-31 | 1990-11-13 | Philip Morris Incorporated | Indicia applying apparatus |
EP0584088B1 (en) * | 1991-02-08 | 1999-10-27 | Cambridge Neuroscience Research, Inc. | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers |
US5753446A (en) * | 1993-04-15 | 1998-05-19 | National Jewish Center For Immunology & Respiratory Medicine | Mitogen ERK kinase kinase (MEKK) assay |
US5616578A (en) * | 1993-08-26 | 1997-04-01 | The Dupont Merck Pharmaceutical Company | Method of treating human immunodeficiency virus infection using a cyclic protease inhibitor in combination with a reverse transcriptase inhibitor |
US6008255A (en) | 1994-01-21 | 1999-12-28 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
US5599984A (en) | 1994-01-21 | 1997-02-04 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
US5574040A (en) * | 1995-01-06 | 1996-11-12 | Picower Institute For Medical Research | Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions |
US6369068B1 (en) * | 1995-06-07 | 2002-04-09 | Smithkline Beecham Corporation | Amino substituted pyrimidine containing compounds |
JP2000510327A (ja) * | 1996-03-12 | 2000-08-15 | スミスクライン・ビーチャム・コーポレイション | 医薬的に活性な化合物の同定方法 |
DE69739734D1 (de) * | 1996-11-15 | 2010-02-25 | Cytokine Pharmasciences Inc | Guanylhydrazone die nützlich sind zur behandlung von mit t-zellen verbundenen krankheiten |
US6180686B1 (en) * | 1998-09-17 | 2001-01-30 | Thomas M. Kurth | Cellular plastic material |
-
1997
- 1997-11-14 DE DE69739734T patent/DE69739734D1/de not_active Expired - Lifetime
- 1997-11-14 AU AU54360/98A patent/AU746647B2/en not_active Expired
- 1997-11-14 US US08/970,973 patent/US6143728A/en not_active Expired - Lifetime
- 1997-11-14 AT AT97948263T patent/ATE454141T1/de active
- 1997-11-14 JP JP52280198A patent/JP2001503775A/ja not_active Ceased
- 1997-11-14 WO PCT/US1997/020670 patent/WO1998020868A1/en active IP Right Grant
- 1997-11-14 CA CA002271693A patent/CA2271693C/en not_active Expired - Lifetime
- 1997-11-14 ES ES97948263T patent/ES2339306T3/es not_active Expired - Lifetime
- 1997-11-14 EP EP97948263A patent/EP0963197B1/en not_active Expired - Lifetime
-
2000
- 2000-11-02 US US09/705,581 patent/US6673777B1/en not_active Expired - Lifetime
-
2003
- 2003-07-16 US US10/619,426 patent/US7741372B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2271693C (en) | 2009-01-20 |
EP0963197A1 (en) | 1999-12-15 |
EP0963197A4 (en) | 2003-04-09 |
EP0963197B1 (en) | 2010-01-06 |
CA2271693A1 (en) | 1998-05-22 |
US20040171695A1 (en) | 2004-09-02 |
DE69739734D1 (de) | 2010-02-25 |
WO1998020868A1 (en) | 1998-05-22 |
US6143728A (en) | 2000-11-07 |
US6673777B1 (en) | 2004-01-06 |
AU746647B2 (en) | 2002-05-02 |
AU5436098A (en) | 1998-06-03 |
ES2339306T3 (es) | 2010-05-18 |
US7741372B2 (en) | 2010-06-22 |
ATE454141T1 (de) | 2010-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001503775A (ja) | T細胞の活性化に関係する疾患を治療するために有用なグアニルヒドラゾン | |
Strle et al. | Interleukin-10 in the brain | |
JP2656938B2 (ja) | dsRNAと逆転写酵素インヒビターを含んで成るHIV感染治療のための医薬組成物 | |
Dinarello et al. | Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer | |
Haines et al. | Cellular response to double‐stranded RNA | |
JP2016522831A (ja) | 炎症を予防および治療するためのクリオピリン阻害剤 | |
US20110059949A1 (en) | Prophylaxis and treatment of infectious diseases | |
Németh et al. | NHE blockade inhibits chemokine production and NF-κB activation in immunostimulated endothelial cells | |
WO1992016226A1 (en) | Il-1 inhibitors | |
JP2005525404A (ja) | Hiv感染およびaidsを処置するためにサイトカインアンタゴニストを使用する方法 | |
JP2010111688A (ja) | 免疫調節剤の用途 | |
EP1406667B1 (en) | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals | |
US20110300142A1 (en) | Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants | |
AU2002300386B2 (en) | Guanylhydrazones useful for treating diseases associated with T cell activation | |
US20030153526A1 (en) | Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1 | |
JP2002538171A (ja) | 抗ウイルス剤の医薬的組合せ | |
JP2023519990A (ja) | 感染に関連する炎症の治療のための方法 | |
Wang et al. | Potent and selective inhibition of Tat-dependent HIV-1 replication in chronically infected cells by a novel naphthalene derivative JTK-101 | |
AU2002362753B9 (en) | Compositions for and methods of treating and preventing sirs/sepsis | |
US7329643B2 (en) | Inhibition of HMGB1 release by fetuin | |
JP5558353B2 (ja) | Lcksh2ドメイン結合の小分子阻害剤 | |
JP2018508518A (ja) | Hiv感染の処置のための方法及び医薬組成物 | |
AU2002362753A1 (en) | Compositions for and methods of treating and preventing sirs/sepsis | |
Bryn et al. | Inhibition of protein kinase A improves effector function of monocytes from HIV-infected patients | |
Kim | CD45-mediated inhibition of HIV-1 Nef signaling in human microglia: Mechanisms and implications for AIDS dementia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041111 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080805 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081105 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081215 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090401 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090526 |